Regency Capital Management Inc. DE Reduces Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA)

Regency Capital Management Inc. DE decreased its holdings in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 2.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 765,055 shares of the company’s stock after selling 20,081 shares during the quarter. Aura Biosciences comprises approximately 3.7% of Regency Capital Management Inc. DE’s holdings, making the stock its 10th largest position. Regency Capital Management Inc. DE owned about 1.54% of Aura Biosciences worth $5,784,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. American International Group Inc. increased its holdings in shares of Aura Biosciences by 27.4% during the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after purchasing an additional 3,782 shares during the period. Trexquant Investment LP grew its position in Aura Biosciences by 64.5% during the fourth quarter. Trexquant Investment LP now owns 17,362 shares of the company’s stock worth $154,000 after buying an additional 6,809 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Aura Biosciences by 14.6% during the second quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock valued at $487,000 after acquiring an additional 8,194 shares during the period. Levin Capital Strategies L.P. raised its holdings in Aura Biosciences by 11.2% in the 1st quarter. Levin Capital Strategies L.P. now owns 111,200 shares of the company’s stock valued at $873,000 after acquiring an additional 11,200 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Aura Biosciences by 26.3% in the 2nd quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock worth $545,000 after acquiring an additional 15,000 shares during the period. Institutional investors and hedge funds own 96.75% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on AURA shares. JMP Securities boosted their price objective on Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a research report on Friday, September 13th. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of Aura Biosciences in a research report on Friday, September 13th. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Aura Biosciences has a consensus rating of “Buy” and a consensus price target of $21.67.

Aura Biosciences Price Performance

Shares of NASDAQ:AURA opened at $8.91 on Tuesday. The business’s fifty day moving average price is $8.71 and its two-hundred day moving average price is $7.91. Aura Biosciences, Inc. has a fifty-two week low of $5.99 and a fifty-two week high of $12.35. The stock has a market capitalization of $441.43 million, a price-to-earnings ratio of -4.79 and a beta of 0.35.

Aura Biosciences (NASDAQ:AURA) last posted its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.04. Research analysts expect that Aura Biosciences, Inc. will post -1.7 EPS for the current fiscal year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.